Maintenance Notice (11:00 PM August 15 - 1:30 AM August 16, 2026 UTC): The website is scheduled for maintenance. The website will be available, but some functions may experience errors. We appreciate your patience and understanding.
Product Document Searching Made Easy by 2D Code! | TCI Chemistry News August 2026 | [Product Highlights] Chain Transfer Agents for Cationic RAFT... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 2207-75-2 | 產品號碼: O0164
Potassium Oxonate
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
性質
| 熔點 | 300 °C |
GHS
相關法規
| RTECS # | RR4580000 |
運輸資料
| HS編碼* | 2933.69-000 |
Application
Potassium Oxonate: An Inhibitor of Orotate Phosphoribosyltransferase (OPRT)
Potassium oxonate is an inhibitor of orotate phosphoribosyltransferase (OPRT) that is an enzyme involved in the biosynthesis of pyrimidine nucleotides and catalyzes the phosphorylation of 5-FU [F0151] to an active metabolite 5-fluorouridine-5'-monophosphate (FUMP). The gastrointestinal toxicity (GIT) of the oral administration of 5-FU is also caused by the phosphorylation by OPRT in the gut wall. Potassium oxonate selectively and competitively inhibits OPRT. As a result, 5-FU associated gastrointestinal toxic effects are reduced. Potassium oxonate is often used as combined agents to enhance the antitumor activity of fluoropyrimidines, such as S-1 (tegafur [F0635] a prodrug of 5-FU, gimeracil [C2243] and potassium oxonate at a molar ratio of 1:0.4:1). (The product is for research purpose only.)
References
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
- Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats
- Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats
- Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats
- Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil
Application
Reagent for hyperuricemia (gout) model
References
- Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents
- Hyperuricemia induced by some antihypertensives and uricosuric drugs in oxonate-treated rats
- Y. Yonetani, M. Ishii, K. Iwaki, Jpn. J. Pharmacol. 1980, 30, 829.
- Use of the uricase-inhibited rat as an animal model in toxicology
- Beneficial effect of rutin on oxonate-induced hyperuricemia and renal dysfunction in mice
PubMed Literature
文檔
產品介紹報導
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
請輸入TCI產品號碼
text.certificate.product.input.placeholder.kishida
4或5個單字節字母數字字符
text.certificate.lotno.input.placeholder.kishida
SDS
產品規格
沒有搜索到 產品規格。
如需更多幫助，請 聯繫我們 。
text.specification.search.errormsg.content.1.kishida
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
text.certificate.analysis.pdf.lotNumber.errorMessage.alphanumeric.kishida
• 請確認您輸入的批號。
• 如果您輸入的信息無誤，請 聯繫我們 。
• text.certificate.analysis.pdf.errormsg.content6.kishida
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
text.certificate.analysis.pdf.lotNumber.errorMessage.alphanumeric.kishida
很抱歉，您搜索的分析圖譜無法提供。